A new review article released on Aug. 7 explores how purinergic signaling pathways may play a central role in the progression of osteoarthritis, potentially offering new avenues for targeted therapies. The review describes an intricate communication network within joints that influences inflammation, cartilage degeneration, bone remodeling, and chronic pain.
Osteoarthritis is the most common form of arthritis and a leading cause of pain and disability worldwide. The review notes that while osteoarthritis was once regarded primarily as a consequence of mechanical wear and tear, it is now understood to involve complex biological processes affecting the entire joint. Purinergic receptors—proteins that respond to molecules released by damaged or stressed cells—are described as regulators of normal joint function that become dysregulated during osteoarthritis, driving inflammation and tissue damage.
The article identifies two major groups of receptors with contrasting roles in joint health. P2 receptors respond to extracellular nucleotides such as ATP and are associated with inflammatory signaling, cartilage breakdown, and pain when excessively activated. In contrast, P1 receptors respond to adenosine and generally support protective processes including maintaining cartilage integrity, reducing inflammation, and promoting tissue repair. According to the review, maintaining a balance between these signaling pathways is essential for healthy joint function.
Specific receptor subtypes are reported to influence different aspects of osteoarthritis: some contribute to inflammatory pathways damaging cartilage or altering bone structure; others are closely linked with persistent pain development. Protective receptor activity may enhance autophagy, improve mitochondrial function, reduce oxidative stress, and help preserve the extracellular matrix vital for cartilage strength.
The authors discuss therapeutic strategies aimed at selectively targeting these pathways by blocking harmful P2 receptor activity while enhancing beneficial P1 receptor effects. They say this approach could address both structural damage and pain more comprehensively than current treatments focused solely on symptom relief. However, they also note that further research is needed to improve drug selectivity for specific receptors, minimize unwanted side effects, and optimize delivery methods for affected joints.
